Overcoming resistance to anti-PD1 blockade in uterine leiomyosarcomas KU Leuven
Uterine leiomyosarcomas (uLMS) are rare tumors, characterized by an aggressive clinical behavior and high risk of hematologic spread. Currently, no highly effective therapeutic agents are available for these patients, which leads to a very poor prognosis and emphasizes the urgent need for new therapeutic options. The onset of immune checkpoint blockade (ICB) has transformed the therapeutic landscape in oncology, showing unprecedented ...